1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Influenza Vaccine Market by Vaccine Type, Type, Technology, Age Group, and Route of Administration : Global Opportunity Analysis and Industry Forecast, 2019-2026

Influenza Vaccine Market by Vaccine Type, Type, Technology, Age Group, and Route of Administration : Global Opportunity Analysis and Industry Forecast, 2019-2026

  • October 2019
  • 226 pages
  • ID: 5828838
  • Format: PDF
  • By Allied Market Research

Summary

Table of Contents

Influenza Vaccine Market by Vaccine Type (Quadrivalent and Trivalent), Type (Seasonal and Pandemic), Technology (Egg-based and Cell-based), Age Group (Pediatric and Adult), and Route of Administration (Injection and Nasal Spray): Global Opportunity Analysis and Industry Forecast, 2019-2026

The global influenza vaccine market was valued at $3.96 billion in 2018, and is projected to reach $6.20 billion by 2026, registering a CAGR of 5.9% from 2019 to 2026.

Influenza, commonly known as flu, is a contagious respiratory infection caused by influenza viruses. Four types of influenza viruses include type A, B, C, and D. The most common types of influenza viruses responsible for seasonal flu each year are type A and B. These viruses enter into the respiratory system of an individual, and are transmitted to other individuals by direct contact or inhalation of virus-laden aerosols. The ideal method to prevent influenza is through vaccination.

The key factors that drive the growth of the global influenza vaccine market include increase in government initiatives to ensure well-being of population, minimal side effects associated with influenza vaccines, advancements in existing vaccines, and development of new vaccines. In addition, upsurge in funding and investments by companies in R&D activities supplements the growth of this market. However, longer timelines required for vaccine production and higher costs associated with the development hinder the growth of the market globally. Conversely, routine immunization programs in developed and developing countries are expected to provide lucrative opportunities for market expansion.

The global influenza vaccines market is segmented into vaccine type, type, technology, age group, route of administration, and region. By vaccine type, it is bifurcated into quadrivalent and trivalent. Depending on type, it is segregated into seasonal and pandemic. As per technology, it is classified into egg-based and cell-based. According to age group, it is divided into pediatric and adult. On the basis of route of administration, it is categorized into injection and nasal spray. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
-This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
-An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
-A comprehensive analysis of the factors that drive and restrain the growth of the global influenza vaccine market is provided.
-An extensive analysis of various regions provides insights that allows companies to strategically plan their business moves.

KEY MARKET SEGMENTS
•By Vaccine type
oQuadrivalent
oTrivalent
•By Type
oSeasonal
oPandemic
•By Technology
oEgg-based
oCell-based
•By Age Group
oPediatric
oAdult
•By Route of Administration
oInjection
oNasal Spray
•By Region
oNorth America
-U.S.
-Canada
-Mexico
oEurope
-Germany
-France
-UK
-Italy
-Spain
-Rest of Europe
oAsia-Pacific
-Japan
-China
-India
-Australia
-South Korea
-Rest of Asia-Pacific
oLAMEA
-Brazil
-Saudi Arabia
-South Africa
-Rest of LAMEA

KEY MARKET PLAYERS
•AstraZeneca Plc.
•Biodiem
•CSL Limited
•Emergent BioSolutions
•F. Hoffmann-La Roche Ltd.
•Gamma Vaccines Pty Ltd.
•GlaxoSmithKline Plc.
•Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
•Novartis AG
•Pfizer, Inc.
•Sanofi Pasteur SA
•Sinovac Biotech Ltd.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2019

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, ...

Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H2 2019

Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Human Cytomegalovirus Envelope Glycoprotein B - Pipeline Review, H2 2019SummaryHuman Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 9 molecules. Out of which approximately ...

Tuberculosis - Pipeline Review, H2 2019

Tuberculosis - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Tuberculosis - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Pipeline Review, H2 2019, provides an overview of the Tuberculosis (Infectious ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on